<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986010</url>
  </required_header>
  <id_info>
    <org_study_id>V160-001</org_study_id>
    <nct_id>NCT01986010</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and immunogenicity of various doses,
      formulations, and routes of administration of Human Cytomegalovirus (HCMV) vaccine V160
      administered in a 3-dose regimen in healthy adults. Each treatment arm of 10 participants
      will be accompanied by a placebo arm of 4 participants. The initial treatment arm of HCMV
      seropositive participants will receive V160 Low Dose without adjuvant by intramuscular
      injection. Escalation of the V160 dose, inclusion of adjuvant, administration by intradermal
      injection, and vaccination of HCMV seronegative participants will be performed only after
      review of safety data of previous treatment arms. The purpose of the study is to identify
      vaccine formulations associated with optimal safety profile and HCMV-specific immune response
      for evaluation in subsequent clinical studies of V160.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2013</start_date>
  <completion_date type="Actual">March 14, 2017</completion_date>
  <primary_completion_date type="Actual">April 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with an Adverse Event (AE)</measure>
    <time_frame>From the time of vaccination up to 14 days after any vaccination (vaccinations are administered on Day 1, Month 1 and Month 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with an Injection-site AE</measure>
    <time_frame>From the time of vaccination up to 14 days after any vaccination (vaccinations are administered on Day 1, Month 1 and Month 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Systemic AE</measure>
    <time_frame>From the time of vaccination up to 14 days after any vaccination (vaccinations are administered on Day 1, Month 1 and Month 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Serious Adverse Event (SAE)</measure>
    <time_frame>From the time of vaccination up to 14 days after any vaccination (vaccinations are administered on Day 1, Month 1 and Month 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of HCMV-specific Neutralizing Antibody</measure>
    <time_frame>1 month after vaccination 3 (vaccination 3 is administered at Month 6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Count of Peripheral Blood Mononuclear Cells Secreting Interferon-Gamma</measure>
    <time_frame>1 month after vaccination 3 (vaccination 3 is administered at Month 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Interferon-Gamma after Stimulation of Whole Blood Sample with Pooled HCMV Antigen Peptides</measure>
    <time_frame>1 month after vaccination 3 (vaccination 3 is administered at Month 6)</time_frame>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>HCMV seropositive (+) V160 Low Dose Intramuscular (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV seronegative (-) V160 Low Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 Medium Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Medium Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 High Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Medium Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 High Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 High Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 Maximum Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 High Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Maximum Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ Placebo IM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- Placebo IM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 Medium Dose Intradermal (ID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Medium Dose ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ Placebo ID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- Placebo ID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Low Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV seropositive (+) V160 Low Dose Intramuscular (IM)</arm_group_label>
    <arm_group_label>HCMV seronegative (-) V160 Low Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Medium Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 Medium Dose IM</arm_group_label>
    <arm_group_label>HCMV- V160 Medium Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 High Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 High Dose IM</arm_group_label>
    <arm_group_label>HCMV- V160 High Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM</intervention_name>
    <description>V160 plus MAPA administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV- V160 Medium Dose plus MAPA 225 µg IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 High Dose plus MAPA 225 µg /dose IM</intervention_name>
    <description>V160 plus MAPA administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 High Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_label>HCMV- V160 High Dose plus MAPA 225 µg IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Maximum Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 Maximum Dose IM</arm_group_label>
    <arm_group_label>HCMV- V160 Maximum Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo IM</intervention_name>
    <description>Placebo administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ Placebo IM</arm_group_label>
    <arm_group_label>HCMV- Placebo IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Medium Dose ID</intervention_name>
    <description>V160 administered as a 0.1 mL intradermal injection</description>
    <arm_group_label>HCMV+ V160 Medium Dose Intradermal (ID)</arm_group_label>
    <arm_group_label>HCMV- V160 Medium Dose ID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo ID</intervention_name>
    <description>Placebo administered as a 0.1 mL intradermal injection</description>
    <arm_group_label>HCMV+ Placebo ID</arm_group_label>
    <arm_group_label>HCMV- Placebo ID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy based on medical history and physical examination

          -  Serologically confirmed to be HCMV seronegative or HCMV seropositive

          -  Agrees to avoid unusual, unaccustomed strenuous, vigorous physical exercise/activity
             from 72 hours before through 72 hours after each dose of study vaccine

          -  Body weight ≥110 lbs (50 kg) and body mass index (BMI) of 19 to 32 kg/m^2

          -  If of reproductive potential, agrees to the following during the study and for 4 weeks
             after the last dose of study vaccine: 1) practice abstinence from heterosexual
             activity, or 2) use or have their partner use 2 allowable methods of birth control
             during heterosexual activity

        Exclusion Criteria:

          -  Has previously received any cytomegalovirus vaccine

          -  Has history of allergic reaction or anaphylactic reaction to any vaccine component
             that required medical intervention

          -  Has history of any severe allergic reaction that required medical intervention

          -  Is pregnant or breastfeeding or expecting to conceive from 2 weeks before the study
             through 1 month after the last dose of study vaccine

          -  Plans to donate eggs or sperm from study start through 1 month after the last dose of
             study drug

          -  Has impairment of immunologic function including, but not limited to autoimmune
             disease, splenectomy, or HIV/AIDS

          -  Received systemic corticosteroids for ≥14 consecutive days and has not completed
             treatment within 30 days of study start

          -  Received immunosuppressive therapy including, but not limited to rapamycin and
             equivalents, tacrolimus, FK-506, fujimycin, or other therapies used for solid
             organ/cell transplant, radiation therapy, immunosuppressive/cytotoxic chemotherapy, or
             other therapy known to interfere with the immune response within 1 year of study start

          -  Has a condition in which repeated venipuncture or injections pose more than minimal
             risk, such as hemophilia, thrombocytopenia or other severe coagulation disorders, or
             significantly impaired venous access

          -  Has a condition that requires active medical intervention or monitoring such as
             diabetes mellitus, autoimmune disease, or a clinically significant chronic medical
             condition that is considered progressive

          -  Has history within the past 5 years or current drug or alcohol abuse

          -  Has major psychiatric illness

          -  Is legally or mentally incapacitated

          -  Has participated in another clinical study in the past 4 weeks, or plans during the
             present study to participate in a treatment-based study or a study in which an
             invasive procedure is performed

          -  Has received valganciclovir, ganciclovir, valacyclovir, foscarnet, or cidofovir from 4
             weeks prior to 1 month following each V160 vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

